Aeruguard is a single-strain inhaled biotherapeutic that treats Pseudomonas aeruginosa and breaks down mucus in Cystic Fibrosis patients. Consisting of a live Lactobacillus hybrid, it is designed specifically to kill Pseudomonas and reduce the viscosity and volume of mucus. Aeruguard also down-regulates the inflammatory immune response created by the Pseudomonas pathogen and reduces scarring in the lungs.
Mybacguard treats nontuberculous mycobacteria (NTM) lung infection associated with cystic fibrosis. It is a live therapeutic microbe delivered directly to infected lungs. This microbe was evolved to thin mucus while both eliminating and preventing further NTM infections. Mybacguard is effective against the most common NTM pathogens, Mycobacterium avium and Mycobacterium abscessus. With the support of a grant from the National Institutes of Health, SciBac is working to establish the safety and effectiveness of this novel treatment in partnership with National Jewish Health, a leading expert on testing drug efficacy in cystic fibrosis lung infections.
SciBac is expanding its pipeline by developing biotherapeutics for other antibiotic resistant diseases.